Potential pitfalls as weight loss drugs go generic
By Constance Talbot
Ozempic, Mounjaro and Wegovy, the drugs on everyone’s lips – but what do they actually do? The saying ‘eyes bigger than your stomach’ doesn’t come from nowhere; instead of focusing on burning calories, these weight-loss drugs work on reducing food intake by diminishing appetite and massively reducing the speed at which the stomach is able to empty food. Fuelled by semaglutide (a synthetic glucagon-like peptide known as GLP-1), the foundation of these injections was built on the treatment of type-2 diabetes by the company Novo Nordisk. The hormone GLP-1 is released from the gut after eating and stimulates the secretion insulin, a hormone released from the pancreas involved in the regulation of blood glucose, whilst simultaneously acting as an appetite-repressing signal in the brain. Ozempic was designed, patented and approved in 2017 as a type-2 diabetes drug, that is still only accessible for those diagnosed with type-2 diabetes in the UK. The work around? Wegovy.
Wegovy, unlike Mounjaro, operates under the same mechanism as Ozempic just with a higher maximum dose, with patients taking Wegovy getting “five times the amount of GLP-1 that they would produce in response to a Thanksgiving dinner”. With the US F.D.A approval for Wegovy to be used as a weight loss drug in 2021, Wegovy hit the market but even in the four-year gap between Ozempic and Wegovy, Doctor’s had already begun prescribing it off label and diagnosing people as ‘pre-diabetic’.
As for the UK, Wegovy was launched in September 2023, closely followed by its sister-drug Mounjaro in November, and became available both on the NHS and privately, through a whole host of big brands ranging from Boots to Morrisons Clinic. Fast forward to 2026, it’s approximated that 1.5 million people in the UK are currently taking weight loss injections – but where do we go from here?
Those taking weight loss drugs can expect to lose approximately a fifth of their starting weight, considerably more than the standard dieter, but can equally expect to put all the weight back on after a year and a half
It’s estimated that 90% of people taking weight loss drugs are paying privately for treatment plans between 1-2 years long. For many, this can really start adding up, as the lowest doses start at around £130 per month for most companies, with this sum only rising as doses increase. But what happens when those 2 years are up and the financial demand starts to take its toll? The BBC has reported that those coming off weight-loss jabs can regain weight “four times faster than those who stop conventional dieting”. To put this into perspective, those taking weight loss drugs can expect to lose approximately a fifth of their starting weight, considerably more than the standard dieter, but can equally expect to put all the weight back on after a year and a half – so is it really worth the cost?
The psychological warfare of weight loss drugs is nothing short of the extreme. For the first time, people are being provided with a path that removes the biggest hurdle of weight loss: the brain. Essentially, Ozempic and Wegovy alike remove the discipline required to diet, but when the GLP-1 starts to wear off, patients have often taken 1 step forward and 2 steps back, due to the artificial GLP-1 causing a drop in the natural GLP-1 levels below what they should normally be, as the body becomes dependent on the artificial version. But before jumping to the extreme, the 2 years that are spent at a lower weight have the potential to reduce the damage on an individual’s joints, heart and kidneys even if this lighter weight cannot be sustained. As nice as this is in theory, like all new medication the long-term effects are still unknown – both the good and bad.
Unfortunately, the trouble of Ozempics doesn’t stop there. Whilst long term effects are of definite concern, a more pressing catch is the side effects. Manipulation of the digestive system comes with a series of gastrointestinal side effects ranging from nausea to ‘sulphur burps’ but for the most part, these are monitored by regular checkups administrated as part of a weight-loss prescription. However, what if weight-loss drugs aren’t prescribed and therefore side effects not monitored? With Novo Nordisk’s patent due to run out this year in India, Canada, China, Brazil and Turkey and from 2031 in the UK, clinicians are worried about the inevitable influx of generic semaglutide products at a much cheaper price.
Currently, the target demographic for weight-loss injections is controlled by BMI regulations which prevent those below this threshold from prescription. This is critically important as weight-loss drugs are only recommended as a health benefit, where significant weight loss would dramatically increase an individual’s overall health and ‘normal’ dieting approaches would not be enough to remedy severe health risks. But with patents coming to an end and a high chance of increase in both supply and demand, the pressure on pharmaceutical research will ramp up, which looms the question of who should be allowed to take weight-loss injections. The next few months propose uncertainty as the line between medical and cosmetic blurs.
Image: Markus Winkler via Pixabay

